|
Bulk drugs and intermediates exports grew 3.76% in FY26
|
|
Gireesh Babu, New Delhi
May 19 , 2026
|
|
|
Exports of bulk drugs and intermediates reported a growth of 3.76% during the financial year 2025-26, reporting a trade surplus of around $600 million for the period.
The bulk drugs and intermediates exports during the 12 months from April, 2025 to March, 2026, stood at $5.08 billion, as against $4.9 billion in the same period of last year, according to data from the ministry of commerce and industry.
Quantity of exports grew 11.1% to 5,10,380.2 MT as against 4,59,449 MT during the comparable period.
Imports during the fiscal year 2025-26 stood at $4.48 billion, registering a decline of 3.4% from $4.64 billion imports reported during the previous fiscal year.
In rupee terms, the growth in exports was around 8.5% at Rs. 45,004.4 crore during the fiscal year, as compared to Rs. 41,494.5crore during the previous fiscal year.
Exports during the fourth quarter of the fiscal year, from January to March, 2026, grew 1.44% to $1.4 billion as against $1.38 billion during the corresponding quarter of previous fiscal year.
Quantity of exports grew 12.4% to 1,39,432 MT compared to 1,24,035 MT during the same quarter a year ago.
In rupee terms, there was a growth of 7.42% during the quarter, at Rs. 12,848 crore as against Rs 11,960.7 crore reported in the fourth quarter of last fiscal year.
Exports during the month of March, 2026 was at $533.6 million compared to $553.76 million during the same month of last year. Quantity of exports grew 14.15% to 52,097 MT as against 45,639.2 MT on a YoY basis.
In rupee terms, the growth was 3.17% to Rs. 4,950 crore compared to Rs. 4,797.7 crore reported during March, 2025.
As reported earlier, the exports during the financial year ended March, 2025 reported a 2.3% growth to $4.9 billion, as compared to $4.79 billion in the previous fiscal year. Quantity, on the other hand, declined 3.2% to 4,59,449 MT as compared to 4,74,617 MT reported during April, 2023 to March, 2024.
The Central government has been emphasising on reducing the imports of essential pharmaceutical raw materials such as bulk drugs, drug intermediates and key starting materials, among others, and has initiated various incentive schemes to support domestic production of these materials.
The Department of Pharmaceuticals has been promoting production of pharma raw materials in the country, including through a production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs) in the country, to support the industry in various aspects regarding ease of doing business and availing the benefits of the Scheme.
It has also announced schemes to promote bulk drug parks in the country, as part of its efforts to promote domestic manufacturing of pharma ingredients.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|